King, CorePharma Settle Skelaxin Suit

Law360, New York (January 8, 2008, 12:00 AM EST) -- King Pharmaceuticals Inc. has dropped one of the infringement cases concerning its muscle relaxant Skelaxin, agreeing to grant a patent license allowing the defendant, CorePharma LLC, to manufacture a generic version of the drug, known as metaxalone, beginning in 2012.

In a filing with the U.S. Securities and Exchange Commission on Jan. 8, King announced it settled its case against CorePharma in the U.S. District Court for the Eastern District of New York on Jan. 2.

On Jan. 8, the parties filed a joint stipulation in...
To view the full article, register now.